SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesmarket

IMMNOV (IMMNOV) News

Follow IMMNOV (IMMNOV) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol IMMNOV Asset market Sector Markets 90 days 7 Updated Nov 04, 2026, 01:00 PM UTC Open live news feed
M Immunovia Rights Issue Targets SEK 63.4M, 78.8% Covered Immunovia's prospectus for a rights issue of approximately SEK 63.4 million was approved and registered. The issue is covered to approximately 78.8%; full subscription would raise approximately SEK 63.4 million before co EQUITY | Nov 04, 2026, 01:00 PM UTC M Immunovia Sets Terms for Rights Issue of Up to SEK 63.4M The issue is priced at SEK 0.06 per unit, comprising two shares and one warrant. Full subscription implies about 75.9% dilution; an extraordinary general meeting must approve the issue. Warrant exercise could raise up to EQUITY | Oct 28, 2026, 07:01 PM UTC L Immunovia (IMMNOV) Launches Partly Guaranteed SEK 63M Rights Issue Immunovia announced a partly guaranteed rights issue of units of about SEK 63M, with subscription set for 9—23 Nov 2026. Carlsquare paused its research coverage until completion.Material DetailsContext by AI AnalystThis NEWS | Sep 29, 2026, 07:52 AM UTC L Immunovia To Carry Out Rights Issue Of About SEK 63 Million Immunovia AB OMXSTO:IMMNOV:Source text:Further company coverage NEWS | Sep 29, 2026, 05:54 AM UTC L Immunovia (IMMNOV) Calls EGM to Approve Dilutive Rights Issue Immunovia AB (publ) will hold an EGM on Oct 29, 2026 to approve a rights issue of units (2 shares + 1 warrant TO 4) and amend Articles to raise capital/share limits. Record date Nov 5; subscription Nov 9—23; TO 4 exercis EQUITY | Sep 28, 2026, 04:35 PM UTC L Immunovia AB (publ) (IMMNOV) Plans SEK 63M Rights Issue, 80% Covered Immunovia will conduct a SEK 63M rights issue of units, subject to EGM approval, with ~SEK 50M (≈80%) covered by undertakings and a bottom guarantee. Proceeds will fund US commercialization of PancreaSure, clinical studi NEWS | Sep 28, 2026, 04:31 PM UTC L Immunovia AB (IMMNOV) Files for Medicare LCD Coverage of PancreaSure Immunovia AB submitted a formal request for a new Local Coverage Determination for PancreaSure, seeking Medicare coverage for its blood test for early detection of pancreatic cancer in high—risk individuals.Material Deta NEWS | Sep 28, 2026, 12:01 PM UTC